US pharmacy benefits manager CVS Health Corp has added new migraine drugs from Teva and Eli Lilly to its list of covered drugs but excluded a rival from Amgen, according to a press report.<
Teva and Neos Therapeutics have reached a confidential settlement and licensing agreement that resolves a patent dispute over the Israeli firm's generic version of Neos’ ADHD drug Cotempla XR-OD
The FDA has approved Celltrion and Teva’s biosimilar of Roche’s breast cancer drug Herceptin, the second potential competitor to the cancer blockbuster in the US.
Eli Lilly has filed a new migraine drug, lasmiditan, with the US regulator, the first drug in its class to be reviewed as a treatment for the condition.
